WCM
TARS icon

Wedge Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Wedge Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
23,796
+4,092
+21% +$261K 0.02% 375
2026
Q1 		$1.38M Buy
+19,704
New +$1.38M 0.03% 407

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wedge Capital Management's TARS Position: Q2 2026 in Review

Wedge Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 21% in Q2 2026, buying an estimated $261K and bringing the position to 23,796 shares worth $1.5M. The position accounts for 0.02% of the portfolio, ranked #375.

Wedge Capital Management first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Wedge Capital Management held 23,796 shares of Tarsus Pharmaceuticals worth $1.5M as of Q2 2026.
  • Wedge Capital Management bought 4,092 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $261K.
  • Tarsus Pharmaceuticals made up 0.02% of Wedge Capital Management's portfolio in Q2 2026, its #375 holding.
  • Wedge Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.